European Hospital Financing Reform - Developments and Business Implications for the Medical Device Industry

  • ID: 28611
  • June 2006
  • Region: Europe
  • 113 Pages
  • HBS Medical Limited
1 of 3

A review of healthcare spending in the countries of the developed world over the last two decades shows continued upward trends.

According to an analysis of projected healthcare spending in 18 countries (not including the USA) the Oecd estimates that, as a direct result of population aging, total healthcare spending will increase by an average of nearly 2 percent of GDP over the period 2000 - 2050 in the countries studied.

In response to the historic and forecast upward trends in health spending, most Oecd countries have sought to rein in growth in public sector spending and have utilised a number of health reforms to this end.

Decentralization of planning, decision-making and operating management is taking place to tackle inefficiencies in health systems (efficiency of healthcare systems is defined as the achievement of maximum outputs for a given level of spending or achievement of comparable outputs at lower cost).

Cost containment measures can be reasonably summarised as relying upon three types of policies: (1) regulation of prices (especially relevant to pharmaceuticals), input resources, and health care service volumes (2) shifts of costs onto READ MORE >

Note: Product cover images may vary from those shown
2 of 3

1. Executive Summary

2. Introduction

3. Healthcare Structures in Europe
3.1 Belgium and the Netherlands
3.2 France
3.3 Germany
3.4 Italy
3.5 United Kingdom
3.6 Scandinavia
3.7 Spain

4. Hospital Financing and the shift to DRG-based reimbursement for services
4.1 Benelux
Legislative reform and business implications
4.2 France
Legislative reform and business implications
4.3 Germany
Legislative reform and business implications
4.4 Italy
Legislative reform and business implications
4.5 United Kingdom
Legislative reform and business implications
4.6 Sweden
Legislative reform and business implications

5. The impact of DRGs on reimbursement in selected disease/treatment areas
5.1 Implantable cardioverter defibrillators
5.1.1 ICD therapy in the treatment of arrhythmia and complications
5.1.2 The role of ICDs in prophylaxis of SCD
5.1.3. Cost-effectiveness assessments
5.1.4 DRG and reimbursement impact on ICD
implantation rates-US Recommendations
5.1.5. European ICD Implant Rates
5.2 Drug-Eluting Stents
5.2.1 Creation of new DRGs to cover stent
reimbursement and encourage utilization
5.3 End stage renal disease (ESRD)
5.3.1 Prevalence and socio-economic aspects of chronic kidney disease
5.3.2 Home vs Hospital Haemodialysis – an assessment of UK guidelines

6. Health Technology Assessment (HTA) – its expanding role in medical device diffusion.
6.1 HTA activity in Europe
6.1.1 Benelux
6.1.2 France
6.1.3 Germany
6.1.4 Italy
6.1.5 Spain
6.1.6 United Kingdom
6.1.7 Scandinavia
6.2 Relevant case studies – The NICE approach and impact

7. The anticipated impact of DRG implementation in Germany
7.1 DRGs in the USA and Australia – Any lessons to be learnt for device manufacturers?

8. Corporate Strategies – Positioning in an era of increasing reform

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • STILLE Surgical Instruments
  • Alcon Incorporated
  • Hoya Surgical Optics, Inc.
  • Hollister Inc.
  • PerkinElmer, Inc.
  • Cyberonics, Inc.